Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ARCT is expected to report 2Q20 loss of $ 0.55 per share from revenue of $ 3.54 million.
For the full year, analysts anticipate top line of $ 15.11 million, while looking forward to loss of $ 2.45 per share bottom line.
Previous Quarter Performance
Arcturus Therapeutics Holdings Inc. disclosed loss for the first quarter of $ 0.67 per share, from the revenue of $ 2.65 million. According to street consensus, ARCT was expected to report 1Q20 loss of $ 0.61 per share from revenue of $ 4.97 million. The bottom line results missed street analysts by $ 0.06 or 9.84 percent, at the same time, top line results fell short of analysts by $ 2.32 million or 46.68 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Arcturus Therapeutics Holdings Inc.
Stock Performance
According to the previous trading day, closing price of ARCT was $ 57.51, representing a 575.79 % increase from the 52 week low of $ 8.51 and a 9.36 % decrease over the 52 week high of $ 63.45.
The company has a market capital of $ 1.40 billion and is part of the Financial sector and REIT – Office industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ARCT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 13th July 2020, initiated by B. Riley at Buy rating, with $ 70.00 target price.
